Co-administration of succinylated gelatine with a 99mTc-bombesin analogue, effects on pharmacokinetics and tumor uptake
The bombesin analogue, [99mTc-GGC]-(Ornithine)3-BN(2 –14), 99mTc-BN-O, targeting gastrin releasing peptide receptors (GRPr) on the surface of tumors, was pre-clinically investigated as potential imaging agent for single photon emission computed tomography (SPECT). In addition, the improvement of its pharmacokinetic profile (PK) was investigated thro ugh the co-administration of a succinylated gelatin plasma expander (Gelofusine), aiming to reduce its kidney accumulation and enhance its tumor-to-normal tissue contrast ratios. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - July 19, 2016 Category: Nuclear Medicine Authors: Christos C. Liolios, Stavros Xanthopoulos, George Loudos, Alexandra D. Varvarigou, Gregory B. Sivolapenko Source Type: research
Co-administration of succinylated gelatine with a 99mTc-bombesin analogue, effects on pharmacokinetics and tumor uptake
The bombesin analogue, [99mTc-GGC]-(Ornithine)3-BN(2–14), 99mTc-BN-O, targeting gastrin releasing peptide receptors (GRPr) on the surface of tumors, was pre-clinically investigated as potential imaging agent for single photon emission computed tomography (SPECT). In addition, the improvement of its pharmacokinetic profile (PK) was investigated through the co-administration of a succinylated gelatin plasma expander (Gelofusine), aiming to reduce its kidney accumulation and enhance its tumor-to-normal tissue contrast ratios. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - July 19, 2016 Category: Nuclear Medicine Authors: Christos C. Liolios, Stavros Xanthopoulos, George Loudos, Alexandra D. Varvarigou, Gregory B. Sivolapenko Source Type: research
Toll Like Receptor Mediated Immune Stimulation can be Visualized in Vivo by [18F]FDG-PET
High uptake of [18F]-2-fluorodeoxyglucose ([18F]FDG) by inflammatory cells is a frequent cause of false positive results in [18F]FDG- Positron-emission tomography (PET) for cancer diagnostics. Similar to cancer cells, immune cells undergo significant increases in glucose utilization following activation e.g. in infectious diseases or after vaccination during cancer therapy. The aim of this study was to quantify certain immune effects in vitro and in vivo by [18F]FDG-PET after stimulation with TLR ligands and specific antibodies. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - July 12, 2016 Category: Nuclear Medicine Authors: Stefanie Pektor, Nicole Bausbacher, Georg Otto, Laura Lawaczeck, Stephan Grabbe, Mathias Schreckenberger, Matthias Miederer Source Type: research
Two anti-angiogenic TKI-PET tracers, [11C]axitinib and [11C]nintedanib: radiosynthesis, in vivo metabolism and initial biodistribution studies in rodents
Tyrosine kinase inhibitors (TKIs) are very attractive targeted drugs, although a large portion of patients remains unresponsive. PET imaging with EGFR targeting TKIs ([11C]erlotinib and [18F]afatinib) showed promise in identifying treatment sensitive tumors. The aim of this study was to synthesize two anti-angiogenic TKI tracers, [11C]axitinib and [11C]nintedanib, and to evaluate their potential for PET. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - July 12, 2016 Category: Nuclear Medicine Authors: Paul Slobbe, Alex J. Poot, Rianne Haumann, Robert C. Schuit, Albert D. Windhorst, Guus A.M.S. van Dongen Source Type: research
Toll Like Receptor Mediated Immune Stimulation can be Visualized in Vivo by [18F]FDG-PET
High uptake of [18F]-2-fluorodeoxyglucose ([18F]FDG) by inflammatory cells is a frequent cause of false positive results in [18F]FDG- Positron-emission tomography (PET) for cancer diagnostics. Similar to cancer cells, immune cells undergo significant increases in glucose utilization following activation e.g. in infectious diseases or after vaccination during cancer therapy. The aim of this study was to quantify certain immune effects in vitro and in vivo by [18F]FDG-PET after stimulation with TLR ligands and specific antibodies. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - July 12, 2016 Category: Nuclear Medicine Authors: Stefanie Pektor, Nicole Bausbacher, Georg Otto, Laura Lawaczeck, Stephan Grabbe, Mathias Schreckenberger, Matthias Miederer Source Type: research
